The biotechnology sector’s fastest-growing segment, immuno-oncology, has become the hottest buzzword for investment in Asia.
The field, that uses the body’s own immune system to help fight cancer, has seen two mega acquisitions in the United States in recent months.
And Hong Kong stock exchange is now tuning into its strong future, with Hong Kong Exchanges and Clearing (HKEX) already agreeing to revamp listing rules that will fast track applications by firms linked with the sector to help more innovative drugs and medical devices developers go public as soon as early this summer, and raise much-needed development cash.
Read more
Comments are closed.